Patents Assigned to Archimedes Development Limited
-
Patent number: 9731869Abstract: A container (100), comprising a thread (120) arranged around an opening (110) for engaging a corresponding thread (120) of a closure (400), more than four retention members (140) arranged around the opening (110), each retention member (140) having an end-face for abutting a member (510) on an interior surface of the closure (400) to impede unthreading of the closure (400), the retention members (140) being arranged such that a tangent (170) to each end-face of the retention members (140) intersects a plane (160, 350) bisecting the container (100) at an obtuse angle (171), wherein the retention members (140) are arranged in first and second groups, the first group (141, 410) comprising one retention member (140) having an end-face substantially parallel to the plane bisecting the container (100), and the second group (142, 420) comprising two or more retention members (140), the first and second groups being arranged on one side of the plane (160, 350), each in a respective quadrant of the container (100), thType: GrantFiled: January 26, 2012Date of Patent: August 15, 2017Assignee: Archimedes Development LimitedInventors: Philip Walsh, Peter Watts
-
Patent number: 8946208Abstract: A composition for intranasal delivery of a drug comprising: includes: (i) the drug; and (ii) a non-aqueous vehicle containing (a) propylene glycol and at least one additional solvent selected from N-methylpyrrolidone, propylene carbonate, dimethyl sulfoxide and at least one propylene glycol fatty acid ester; (b) from about 40 to 100% by volume of N-methylpyrrolidone; or (c) from about 40 to 100% by volume of dimethyl sulfoxide (DMSO).Type: GrantFiled: August 29, 2008Date of Patent: February 3, 2015Assignee: Archimedes Development LimitedInventors: Jonathan Castile, Alan Smith, Yu-Hui Cheng, Peter James Watts
-
Patent number: 8710028Abstract: A powder composition for intranasal delivery includes a benzodiazepine drug and chitosan, a salt of chitosan, a derivative of chitosan or a salt of a derivative of chitosan.Type: GrantFiled: August 29, 2008Date of Patent: April 29, 2014Assignee: Archimedes Development LimitedInventors: Peter James Watts, Yu-Hui Cheng, Alan Smith, Jonathan Castile
-
Patent number: 8709996Abstract: The present invention provides a solid composition for oral administration comprising: (i) a drug compound; (ii) chitosan or a derivative thereof or a salt of chitosan or salt of a derivative of chitosan; and (iii) an organic acid. Preferably the drug compound is a polar molecule having a molecular weight of 1 KDa or less, a peptide, a protein or a polysaccharide. The compositions of the invention provide enhance absorption of the drug compound.Type: GrantFiled: April 23, 2010Date of Patent: April 29, 2014Assignee: Archimedes Development LimitedInventors: Michael Leane, Alan Smith, Lisbeth Illum
-
Publication number: 20130313287Abstract: A container (100), comprising a thread (120) arranged around an opening (110) for engaging a corresponding thread (120) of a closure (400), more than four retention members (140) arranged around the opening (110), each retention member (140) having an end-face for abutting a member (510) on an interior surface of the closure (400) to impede unthreading of the closure (400), the retention members (140) being arranged such that a tangent (170) to each end-face of the retention members (140) intersects a plane (160, 350) bisecting the container (100) at an obtuse angle (171), wherein the retention members (140) are arranged in first and second groups, the first group (141, 410) comprising one retention member (140) having an end-face substantially parallel to the plane bisecting the container (100), and the second group (142, 420) comprising two or more retention members (140), the first and second groups being arranged on one side of the plane (160, 350), each in a respective quadrant of the container (100), thType: ApplicationFiled: January 26, 2012Publication date: November 28, 2013Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Philip Walsh, Peter Watts
-
Patent number: 8491932Abstract: An oral drug delivery composition includes a sustained release component which includes a corticosteroid drug and which is contained within a capsule that has been treated so that the sustained release component is predominately released from the capsule in the intestine following oral administration. A drug delivery composition for delivering a corticosteroid drug to the intestine also includes: (a) a sustained release component comprising a corticosteroid drug, an alkali-containing ethylcellulose material and an acid; and (b) a delayed release component which substantially prevents release of the sustained release component until the composition reaches the intestine following oral administration. The compositions of the invention are useful for treating inflammatory diseases of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis, and for treating glomerulonephritis.Type: GrantFiled: May 7, 2009Date of Patent: July 23, 2013Assignee: Archimedes Development LimitedInventors: Peter Watts, Ann Margaret Dyer
-
Patent number: 8481070Abstract: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.Type: GrantFiled: September 30, 2009Date of Patent: July 9, 2013Assignee: Archimedes Development LimitedInventors: Ann Margaret Dyer, Peter James Watts, Yu-Hui Cheng, Alan Smith
-
Patent number: 8460702Abstract: Sustained release pharmaceutical compositions contain a drug; microcrystalline cellulose; a diluent (such as starch); a glidant (such as talc); and one or more of ethylcellulose, stearic acid and a salt of stearic acid. Preferred drugs include those that exhibit a low degree of solubility combined with a high potency, particularly thyroid hormones, such as liothyronine.Type: GrantFiled: December 15, 2006Date of Patent: June 11, 2013Assignee: Archimedes Development LimitedInventors: Alan Smith, Ann Margaret Dyer
-
Patent number: 8309108Abstract: A liquid aqueous formulation for the intranasal administration of apomorphine includes: (a) at least about 15 mg/ml of apomorphine; and (b) a solubilising agent selected from (i) at least one polyoxyethylene-polyoxypropylene copolymer (poloxamer); (ii) at least one cyclodextrin; and (iii) at least one cyclodextrin together with chitosan. The formulations of the invention can be used in the treatment or management of Parkinson's disease and erectile dysfunction.Type: GrantFiled: November 10, 2008Date of Patent: November 13, 2012Assignee: Archimedes Development LimitedInventors: Peter Watts, Yu-Hui Cheng
-
Publication number: 20120277267Abstract: A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: ApplicationFiled: July 3, 2012Publication date: November 1, 2012Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James WATTS, Jonathan David CASTILE, William Columbus Ian LAFFERTY, Alan SMITH
-
Publication number: 20120270903Abstract: An intranasnal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: ApplicationFiled: July 3, 2012Publication date: October 25, 2012Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James WATTS, Jonathan David CASTILE, William Columbus Ian LAFFERTY, Alan SMITH
-
Patent number: 8216604Abstract: A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: GrantFiled: March 13, 2008Date of Patent: July 10, 2012Assignee: Archimedes Development LimitedInventors: Peter James Watts, Jonathan David Castile, William Columbus Ian Lafferty, Alan Smith
-
Publication number: 20120055929Abstract: A child resistant container (10) has a container cavity (20) for the receipt of one or more items to be stored therein. The container cavity (20) is defined by a pair of lids (14, 16) which are hingedly connected to one another. Primary lock means (50) includes a first lock assembly on one lid (14, 16) which engages with a second lock assembly on the other lid (14, 16). A primary lock actuation includes an externally open topped pocket (60) formed in the body of said one lid (14, 16). The pocket (60) has a pocket side wall (62) which is resiliently deflectable from a lock position to an unlock position. The pocket (60) is shaped and sized to permit a finger of an operative to enter the pocket (60) to effect deflection of the pocket side wall (62) to its unlock position.Type: ApplicationFiled: February 4, 2010Publication date: March 8, 2012Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Paul Hayton, Philip Walsh, Tom Walker, Christopher Althorpe
-
Publication number: 20120024724Abstract: Embodiments of the present invention provide a container for liquid medicine disposal, wherein the container has one or more interior surfaces associated with activated carbon cloth for capturing a drug dissolved in the liquid medicine. Embodiments of the present invention are particularly intended for use when dispensing a medicine spray, wherein the container must be held inverted whilst dispensing the spray.Type: ApplicationFiled: August 2, 2011Publication date: February 2, 2012Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Ian R. BEARDSALL, Robert J. WHITWOOD, Sandra D. EVANS, Peter WATTS, Alan Smith
-
Patent number: 8034371Abstract: The present invention provides compositions for the intranasal administration of zolpidem or a pharmaceutically acceptable salt thereof. Preferred compositions of the invention are in the form of aqueous solutions. Optionally the compositions of the invention comprise a cyclodextrin and/or chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention insomnia or the treatment of neurological disorders such as those arising from brain trauma, stroke and spinocerebellar ataxia or in the treatment of Parkinson's disease.Type: GrantFiled: December 23, 2004Date of Patent: October 11, 2011Assignee: Archimedes Development LimitedInventors: Jonathan David Castile, Yu-Hui Cheng, Paul George Jenkins, Alan Smith, Peter James Watts
-
Publication number: 20110182857Abstract: Liquid pharmaceutical compositions for administration to a mucosal surface, including a therapeutic agent and a pectin with a low degree of esterification are described. Such compositions gel, or can be adapted to gel, at the site of application in the absence of an extraneous source of divalent metal ions.Type: ApplicationFiled: April 1, 2011Publication date: July 28, 2011Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter James WATTS, Lisbeth ILLUM
-
Patent number: 7947257Abstract: Compositions are provided for the intranasal administration of granisetron or a pharmaceutically acceptable salt thereof. Preferred compositions are in the form of an aqueous solution. Optionally, the compositions comprise chitosan, a salt or derivative thereof or a salt of a derivative of chitosan. The compositions can be used for the treatment or prevention of nausea and/or vomiting.Type: GrantFiled: December 3, 2004Date of Patent: May 24, 2011Assignee: Archimedes Development LimitedInventors: Peter James Watts, Alan Smith, Jonathan Castile
-
Publication number: 20110104269Abstract: An oral drug delivery composition includes a sustained release component which includes a corticosteroid drug and which is contained within a capsule that has been treated so that the sustained release component is predominately released from the capsule in the intestine following oral administration. A drug delivery composition for delivering a corticosteroid drug to the intestine also includes: (a) a sustained release component comprising a corticosteroid drug, an alkali-containing ethylcellulose material and an acid; and (b) a delayed release component which substantially prevents release of the sustained release component until the composition reaches the intestine following oral administration. The compositions of the invention are useful for treating inflammatory diseases of the gastrointestinal tract, such as Crohn's disease and ulcerative colitis, and for treating glomerulonephritis.Type: ApplicationFiled: May 7, 2009Publication date: May 5, 2011Applicant: ARCHIMEDES DEVELOPMENT LIMITEDInventors: Peter Watts, Ann Margaret Dyer
-
Patent number: 7838643Abstract: The present invention relates to novel quaternized polymers, especially of chitin/chitosan type, and to carbohydrate polymers carrying quaternized ammonium groups, especially piperazinium groups. Such polymers are characterized i.a. by improved solubility characteristics.Type: GrantFiled: August 31, 2006Date of Patent: November 23, 2010Assignee: Archimedes Development LimitedInventors: Jukka Holappa, Tomi Järvinen, Tapio Nevalainen, Jouko Savolainen, Rustam Safin
-
Patent number: D663943Type: GrantFiled: December 29, 2009Date of Patent: July 24, 2012Assignee: Archimedes Development LimitedInventors: Philip Walsh, Christopher Althorpe, Tom Walker, Paul Hayton